Non-avian-derived hyaluronan for the treatment of osteoarthritis of the knee

Expert Review of Clinical Immunology

Volumn 6, Issue 1, 2010, Pages 21-27

  Altman, Roy D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Euflexxa ; Hyaluronan; Knee pain; Osteoarthritis

Indexed keywords

EUFLEXXA; HYALURONIC ACID; UNCLASSIFIED DRUG;

ARTHRALGIA; BACKACHE; BIOENGINEERING; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG PURIFICATION; DRUG SAFETY; HUMAN; JOINT EFFUSION; KNEE OSTEOARTHRITIS; PREVALENCE; REVIEW;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTERIAL; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VISCOSUPPLEMENTATION; VISCOSUPPLEMENTS;

EID: 77649127706     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.78     Document Type: Review

References (31)

1. Murphy L, Schwartz TA, Helmick CG et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 59(9), 1207-1213 (2008).
2. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 54, 226-229 (2006).
3. Lawrence RC, Felson DT, Helmick CG et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58(1), 26-35 (2008).
4. Balazs EA, Weiss C. Elastoviscous hyaluronan in the synovium in health and disease. In: The Many Faces of Osteoarthritis. Hascall VC, Kuettner KE (Eds). Birkhauser Verlag, Basel, Switzerland, 189-206 (2002).
5. Neustadt DH, Altman R. Intra-articular therapy. In: Osteoarthritis: Diagnosis and Medical/Surgical Management (4th Edition). Moskowitz RW, Altman RD, Hochberg MC, Buckwalter JA, Goldberg VM (Eds). Lippincott Williams & Wilkins, PA, USA, 287-302 (2006).
6. Gerwin N, Hops C, Lucke A. Intraarticular drug delivery in osteoarthritis. Adv. Drug Deliv. Rev. 58, 226-242 (2006).
7. Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Sem. Arthritis Rheum. 32, 10-37 (2002).
8. The Merck Manual of Diagnosis and Therapy (18th edition). Beers MH (Ed.). Merck Research Laboratories, Whitehouse Station, NJ, USA, 294-297 (2006).
9. Dieppe PA, Lohmander S. Pathogenesis and management of pain in osteoarthritis. Lancet 365, 965-973 (2005).
10. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 290, 2443-2454 (2003).
11. Centers for Disease Control and Prevention. National and state medical expenditures and lost earnings attributer to arthritis and other rheumatic conditions - United States, 2003. MMWR 56(1), 4-7 (2007).
12. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. Arthritis Rheum. 43(9), 1905-1915 (2000).
13. Jordan KM, Arden NK, Doherty M et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. 62, 1145-1155 (2003). (Pubitemid 37500619)
14. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidencebased, expert consensus guidelines. Osteoarthr. Cartil. 16, 137-162 (2008).
15. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee (non-arthroplasty). Full guideline. 6 December 2008.
16. Simon LS, Strand V. The pharmacologic treatment of osteoarthritis. In: Osteoarthritis: Diagnosis and Medical/ Surgical Management (4th Edition). Moskowitz RW, Altman RD, Hochberg MC, Buckwalter JA, Goldberg VM (Eds). Lippincott, Williams & Wilkins, PA, USA, 268-286 (2006).
17. Pennington B. Baby boomers stay active, and so do their doctors. The New York Times. 16 April 2006.
18. Arnold W, Fullerton DS, Holder S, May CS. Viscosupplementation: managed care issues for osteoarthritis of the knee. J. Manag. Care Pharm. 13(4 Suppl.), S3-S19 (2007).
19. Band P, Atkin DM. Intra-articular hyaluronan injections for osteoarthritis of the knee: issues for coverage policy and utilization. J. Manag. Care Pharm. 11(2 Suppl.), 3-18 (2008).
20. Kim S. Changes in surgical loads and economic burden of hip and knee replacements in the US: 1997-2004. Arthritis Rheum. 59(4), 481-488 (2008).
21. Goldberg VM, Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthr. Cartil. 13, 216-224 (2005).
22. Aggarwal A, Sempowski IP. Hyaluronic acid injections for knee osteoarthritis. Can. Fam. Physician 50, 249-256 (2004).
23. Campbell J, Ruddock B. Hyaluronic acid products for osteoarthritis of the knee. CPJ/RPC 140(3), 194-196 (2007).
24. Kolarz G, Kotz R, Hochmayer I. Longterm benefits and repeated treatment cycles of intra-articular sodium hyaluronate (Hyalgan) in patients wtih osteoarthritis of the knee. Semin. Arthritis Rheum. 32(5), 310-319 (2003).
25. Brockmeier SF, Shaffer BS. Viscosupplementation therapy for osteoarthritis. Sports Med. Arthrosc. 14, 155-162 (2006).
26. Moskowitz RW. Hyaluronic acid supplementation. Curr. Rheumatol. Rep. 2(6), 466-471 (2000).
27. Schoonmaker M. The US Approval Process for Medical Devices: Legislative Issues and Comparison with the Drug Model. Congressional Research Service. Order Code RL32826. March 3 2005.
28. Kaplan AV, Baim KS, Smith JJ et al. Medical device development. From prototype to regulatory approval. Circulation 109, 3068-3072 (2004).
29. Tamir E, Robinson D, Koren R, Agar G, Halperin N. Intra-articular hyaluronan injections for the treatment of osteoarthritis of the knee: a randomized, double blind, placebo controlled study. Clin. Exp. Rheumatol. 19, 265-270 (2001).
30. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthr. Cartil. 14, 154-162 (2006).
31. Altman RD, Rosen JE, Block DA, Hatoum HT, Korner P. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA® for the treatment of painful osteoarthritis of the knee, with an open-label safety extension (The FLEXX Trial). Semin. Arthritis Rheum. 39(1), 1-9 (2009).